LOS ANGELES- HYTN Innovations Inc., a pharmaceutical company specializing in cannabis-derived products, has entered into strategic supply agreements and completed vendor qualifications with two cannabis cultivators, securing a minimum of 4,000 kilograms of cannabis for the German market. This initiative aligns with HYTN’s strategic transition into international pharmaceutical sales and enhances its manufacturing scope for global expansion.
The agreements, established in February 2025, underwent HYTN’s qualification process, including comprehensive site audits, quality control evaluations, and verification of compliance with Good Agricultural and Collection Practices (GACP) to ensure adherence to German pharmacopeia standards. The cultivators qualified for the German market are Klonetics Plant Science Inc. and another Kelowna-based company that has requested non-disclosure.
With qualification complete, the approved cultivators will commence production, focusing on high-potency cultivars tailored to meet the needs of German patients. HYTN’s Good Manufacturing Practice (GMP) certification ensures that all cannabis destined for Germany will adhere to the highest pharmaceutical standards, meeting the country’s regulatory requirements.
Germany’s medical cannabis sector is experiencing rapid growth, driven by increasing patient adoption, expanded physician prescribing, and broadening pharmacy distribution. In the third quarter of 2024, Germany imported 20,000 kilograms of medical cannabis, more than double the quarterly average prior to the April 2024 regulatory reforms, indicating surging demand for compliant pharmaceutical cannabis products.
